- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02525094
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis (ALLEVIAD)
January 19, 2018 updated by: MedImmune LLC
A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of MEDI9929 administered subcutaneously to adult subjects with moderate to severe Atopic Dermatitis.
Subjects will be randomized in a 1:1 fashion and will be stratified at screening.
Approximately 100 subjects are planned to be randomized at approximately 35 sites in 6 countries
Study Type
Interventional
Enrollment (Actual)
113
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
ACT, Australia, 02606
- Research Site
-
Liverpool, Australia, 2170
- Research Site
-
Woolloongabba, Australia, 04102
- Research Site
-
-
-
-
-
Quebec, Canada, G1V 4X7
- Research Site
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Research Site
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6L2
- Research Site
-
-
-
-
-
Berlin, Germany, 10117
- Research Site
-
Frankfurt/Main, Germany, 60590
- Research Site
-
Gera, Germany, 07548
- Research Site
-
Hannover, Germany, 30625
- Research Site
-
Leipzig, Germany, 04103
- Research Site
-
München, Germany, 80337
- Research Site
-
Münster, Germany, 48149
- Research Site
-
-
-
-
-
Debrecen, Hungary, 4032
- Research Site
-
Kaposvár, Hungary, 7400
- Research Site
-
Miskolc, Hungary, 3529
- Research Site
-
Pécs, Hungary, 7632
- Research Site
-
Szeged, Hungary, 6720
- Research Site
-
Szombathely, Hungary, 9700
- Research Site
-
-
-
-
-
Tauranga, New Zealand, 3143
- Research Site
-
Wellington, New Zealand, 6021
- Research Site
-
-
-
-
Florida
-
North Miami Beach, Florida, United States, 33162
- Research Site
-
Tampa, Florida, United States, 33624
- Research Site
-
-
Illinois
-
Arlington Hts, Illinois, United States, 60005
- Research Site
-
-
Indiana
-
Carmel, Indiana, United States, 46032
- Research Site
-
Indianapolis, Indiana, United States, 46256
- Research Site
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28277
- Research Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- AD meeting Hanifin and Rajka criteria
- Age 18-75 years inclusive at screening
- Atopic dermatitis that affects greater than/equal to 10% body surface area
- Moderate to severe AD
- Effective birth control in line with protocol details
Exclusion Criteria:
- Active dermatologic conditions which may confuse the diagnosis of Atopic Dermatitis
- Hepatitis B, C or HIV
- Pregnant or breastfeeding
- History of anaphylaxis following any biologic therapy
- History of clinically significant infections within 4 weeks prior to Visit 3
- Diagnosis of helminth parasitic infection within 6 months to screening
- History of Cancer except basal cell
- Receipt of any marketed or investigational biologic agent within 4 months to visit 3
- Any clinically relevant abnormal finding
- Major surgery within 8 weeks prior to Visit 1
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MEDI9929 280 mg
Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
|
Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
|
Placebo Comparator: Placebo
Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
|
Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 12
Time Frame: Baseline (Day 1) and Week 12
|
The eczema area and severity index (EASI) evaluates 4 natural anatomical regions for severity (0 [none] to 3 [severe]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification).
The total score is the sum of the four body-region scores, maximum=72, minimum=0.
The higher values indicating more severe disease.
The EASI50 responder defined as a participant who achieved at least 50% reduction in EASI score from baseline.
|
Baseline (Day 1) and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving >= 75 % Reduction From Baseline in EASI75 at Week 12
Time Frame: Baseline (Day 1) and Week 12
|
The EASI evaluates 4 natural anatomical regions for severity (0 [none] to 3 [severe]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification).
The total score is the sum of the four body-region scores, maximum=72, minimum=0.
The higher values indicating more severe disease.
The EASI75 responder defined as a participant who achieves at least a 75% reduction in EASI score from baseline.
|
Baseline (Day 1) and Week 12
|
Mean Change From Baseline in EASI Total Score at Week 12
Time Frame: Baseline (Day 1) and Week 12
|
The EASI evaluates 4 natural anatomical regions for severity (0 [none] to 3 [severe]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification).
The total score is the sum of the four body-region scores, maximum=72, minimum=0.
The higher values indicating more severe disease.
|
Baseline (Day 1) and Week 12
|
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline
Time Frame: Baseline (Day 1) and Week 12
|
The investigator's global assessment (IGA) allows investigators to assess overall disease severity at one given time point and consists of a 5-point severity scale from clear to severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease).
A participant has IGA response if they achieve a score of 0 (clear) or 1 (almost clear) and at least a 2-grade reduction from baseline.
|
Baseline (Day 1) and Week 12
|
Mean Change From Baseline in the Scoring of Atopic Dermatitis (SCORAD) at Week 12
Time Frame: Baseline (Day 1) and Week 12
|
The scoring of atopic dermatitis (SCORAD) is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD).
The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms.
The range of the SCORAD is 0-103, where 0 indicates no eczema.
The higher values indicating more severe disease.
|
Baseline (Day 1) and Week 12
|
Percentage of Participants Achieving >= 50% Reduction From Baseline in SCORAD 50
Time Frame: Baseline (Day 1) and Week 12
|
The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD).
The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms.
The range of the SCORAD is 0-103, where 0 indicates no eczema.
The higher values indicating more severe disease.
The SCORAD 50 responder defined as a participant who achieves at least a 50% reduction in SCORAD score from baseline.
|
Baseline (Day 1) and Week 12
|
Percentage of Participants Achieving >= 75% Reduction From Baseline in SCORAD 75
Time Frame: Baseline (Day 1) and Week 12
|
The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD).
The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms.
The range of the SCORAD is 0-103, where 0 indicates no eczema.
The higher values indicating more severe disease.
The SCORAD 75 responder is defined as a participant who achieves at least a 75% reduction in SCORAD score from baseline.
|
Baseline (Day 1) and Week 12
|
Mean Change From Baseline in Average Pruritus Numeric Rating Scale (NRS) at Week 12
Time Frame: Baseline (Day 1) and Week 12
|
Pruritus is assessed using an Numeric Rating Scale (NRS) (0 - 10) with 0= no itch and 10= worst imaginable itch.
Daily pruritus assessments were summarized as weekly peak score and a change from baseline in weekly peak score was calculated.
|
Baseline (Day 1) and Week 12
|
Mean Change From Baseline in 5-D Pruritus Score at Week 12
Time Frame: Baseline (Day 1) and Week 12
|
The 5-D pruritus scale is a brief questionnaire designed to assess itch.
This scale takes into account the multidimensional nature of pruritus, its impact on quality of life, and is capable of detecting change over time.
The 5-D pruritus scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus).
The total 5-D score was obtained by scoring each of the domains separately and then summing them together.
5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus).
The higher values indicating more severe pruritus.
|
Baseline (Day 1) and Week 12
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Time Frame: From treatment administration (Day1) to 22 weeks
|
An Adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of investigational product, whether or not considered related to investigational product.
Serious adverse event is any AE that resulted in:death;inpatient hospitalization or prolongation of existing hospitalization;persistent or significant disability or incapacity;is life-threatening;is a congenital anomaly/birth defect in offspring of a study participant;or was an important medical event that may not have resulted in death, threatened life,or required hospitalization and that, based on appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent one of outcomes above.
TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug until Week 22.
|
From treatment administration (Day1) to 22 weeks
|
Mean Trough Serum Concentration of MEDI9929
Time Frame: Week 0 (Pre dose), Weeks 4, 8, and 12 (post dose)
|
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
|
Week 0 (Pre dose), Weeks 4, 8, and 12 (post dose)
|
Number of Participants Who Developed Detectable MEDI9929 Anti-drug Antibodies
Time Frame: Baseline (Day 1) to Week 22
|
A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study period.
|
Baseline (Day 1) to Week 22
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Roderick Mcphee, MD, MedImmune LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 15, 2015
Primary Completion (Actual)
May 9, 2016
Study Completion (Actual)
July 15, 2016
Study Registration Dates
First Submitted
July 29, 2015
First Submitted That Met QC Criteria
August 13, 2015
First Posted (Estimate)
August 17, 2015
Study Record Updates
Last Update Posted (Actual)
February 15, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D5240C00001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on MEDI9929
-
MedImmune LLCAmgenCompletedAsthmaUnited States, Slovakia, Israel, South Africa, Ukraine, Japan, Czechia, Hungary, Bulgaria, Serbia, Latvia, Lithuania
-
MedImmune LLCAmgenCompleted
-
AstraZenecaParexelRecruiting
-
Celeste PorsbjergLund University; University of Copenhagen; University of Newcastle, AustraliaCompleted
-
AstraZenecaAmgenRecruitingAsthmaUnited States, Poland, Korea, Republic of, Spain, China, France, United Kingdom, Canada, Netherlands, Argentina, Mexico, Brazil, Hungary, Japan, Philippines, South Africa, Colombia
-
AstraZenecaMedImmune LLCCompleted
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedCat Allergy | Cat HypersensitivityUnited States